VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
Abstract Background There is an urgent need for objective markers of Alzheimer’s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. Previously, GluA4 and neuronal pentraxin...
Main Authors: | Alberto Lleó, Maria Carmona-Iragui, Laura Videla, Susana Fernández, Bessy Benejam, Jordi Pegueroles, Isabel Barroeta, Miren Altuna, Silvia Valldeneu, Mei-Fang Xiao, Desheng Xu, Raúl Núñez-Llaves, Marta Querol-Vilaseca, Sònia Sirisi, Alexandre Bejanin, M. Florencia Iulita, Jordi Clarimón, Rafael Blesa, Paul Worley, Daniel Alcolea, Juan Fortea, Olivia Belbin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-021-00861-0 |
Similar Items
-
Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
by: Olivia Belbin, et al.
Published: (2020-08-01) -
Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
by: Bessy Benejam, et al.
Published: (2020-01-01) -
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
by: Alberto Lleó, et al.
Published: (2021-07-01) -
YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies
by: Marta Querol-Vilaseca, et al.
Published: (2017-06-01) -
Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
by: Jordi Pegueroles, et al.
Published: (2020-01-01)